Stockreport

Kala Pharmaceuticals Announces Update to KPI-121 0.25% Development Plan

Kala Pharmaceuticals, Inc.  (KALA) 
Last kala pharmaceuticals, inc. earnings: 2/12 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.kalarx.com
PDF – Expects to submit NDA for KPI-121 0.25% in the second half of 2018 – – Expects to initiate Phase 3 STRIDE 3 trial in the third quarter of 2018 [Read more]